Amylx Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Synchrony Financial trades at $78.6 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 9.7× Amylx Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.73% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SYF | |
|---|---|---|
Market Cap | $2.64B | $25.53B |
Sector | Health | Financials |
52-Week High | $24.19 | $88.47 |
52-Week Low | $7.82 | $63.78 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 1.73% |
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →